Sign up for updates. Be part of our community.

Adaptimmune secures $104 million in Series A Financing

(Oxford, UK and Philadelphia, PA, 25 September 2014). Adaptimmune Limited, a leading biotechnology company focused on the use of T-cell therapy to treat cancer and infectious disease, today announced the completion of a $104 million Series A financing round. Click here to read more.

Media Contact:

Kristen Fitch

Kristen Fitch

Director, Marketing